Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
| Autor: | Anouk N A van der Horst-Schrivers, Karin Eijkelenkamp, Thera P. Links, Thamara E. Osinga |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adrenal Gland Neoplasms Succinic Acid Reviews Pheochromocytoma Review 030105 genetics & heredity medicine.disease_cause Germline Paraganglioma 03 medical and health sciences Biomarkers Tumor Genetics medicine Humans Metabolomics Genetic Predisposition to Disease Epigenetics Carcinoma Renal Cell Germ-Line Mutation Genetics (clinical) Mutation SDH mutation biology Succinate dehydrogenase Cancer succinate medicine.disease Kidney Neoplasms Mitochondria oncometabolites Succinate Dehydrogenase 030104 developmental biology biology.protein Cancer research Carcinogenesis Signal Transduction |
| Zdroj: | Clinical Genetics |
| ISSN: | 1399-0004 0009-9163 |
| Popis: | Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. Germline SDHx mutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro‐intestinal stromal tumors. The SDHx genes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dysfunction and cancer. Accumulation of succinate is the hallmark of tumorigenesis in PGL and PCC. Succinate accumulation inhibits several α‐ketoglutarate dioxygenases, thereby inducing the pseudohypoxia pathway and causing epigenetic changes. Moreover, SDH loss as a consequence of SDHx mutations can lead to reprogramming of cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and other metabolites can be measured in tumor tissue, plasma and urine with different techniques. Furthermore, these pathophysiological characteristics provide insight into therapeutic targets for metastatic disease. This review provides an overview of the pathophysiology and clinical implications of oncometabolite succinate in SDHx mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text